Becton, Dickinson and Co. plans to increase its Wilson headcount to keep up with anticipated demand for its newly approved injectables. That’s according to our exclusive interview with Mark Sebree, the Franklin Lakes, N.J.-based president of the company’s new wholly owned subisidiary, BD Rx. He says the approval announcement isn’t just big news for BD - it’s big news for Wilson, where the facility’s headcount is increasing from 115 to 140 by the end of the year. “We’re very much in a growth mode,” he says. reiterating that the announced antihistamine approval is just one of an anticipated 20 to 30 products, and that the entire new injectables line will be developed and manufactured in Wilson. “The growth will be somewhat dependent on the market we capture.”
